Central neural blockade in patients with a drug-induced alteration of coagulation: Third edition of the Belgian Association for Regional Anaesthesia (BARA) guidelines

Acta Anaesthesiologica Belgica

Volumn 62, Issue 4, 2011, Pages 175-191

  Vandermeulen, E ^a   Decoster, J ^a   Dewandre, P Y ^b   Ickx, B E ^c   Vercauteren, M ^d   Verhamme, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; ANTIVITAMIN K; APIXABAN; ARGATROBAN; ASA MYLAN; ASA SANDOZ; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARDEGIC; CARDIOASPIRINE; CARDIPHAR; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; DANAPAROID; DIPYRIDAMOLE; DISPYRIDAMOLE EG; ENOXAPARIN; EPTIFIBATIDE; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LYSINE ACETYLSALICYLATE; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; PRASUGREL; RETEPLASE; RIVAROXABAN; SEDERGINE; TAMPYRINE; TENECTEPLASE; THROMBIN INHIBITOR; TICAGRELOR; TICLOPIDINE; TINZAPARIN; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; WARFARIN;

ANESTHESIA; BLOOD CLOTTING; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL BLOOD VESSEL MALFORMATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HEPARINIZATION; HERBAL MEDICINE; HUMAN; INDWELLING CATHETER; KIDNEY FUNCTION; LAMINECTOMY; NEUROIMAGING; NEUROMUSCULAR BLOCKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PEROPERATIVE CARE; POINT OF CARE TESTING; POSTOPERATIVE CARE; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; SPINAL HEMATOMA; STROKE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANESTHESIA, CONDUCTION; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; FIBRINOLYTIC AGENTS; HEMATOMA; HUMANS; THROMBOEMBOLISM;

EID: 84857662399     PISSN: 00015164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Anonymous, Belgian guidelines concerning drug induced alteration of coagulation and central neuraxial anesthe -sia. Belgian Society for Anesthesia and Resuscitation, ACTA ANAESTHESIOL. BELG., 51, 101-104, 2000.
2. Vandermeulen E., Singelyn F., Vercauteren M., Brichant J. F., Ickx B. E., Gautier P., Belgian guidelines concerning central neural blockade in patients with drug-induced alteration of coagulation : an update, ACTA ANAESTHESIOL. BELG., 56, 139-146, 2005. (Pubitemid 40943861)
3. Cameron C. M., Scott D. A., McDonald W. M., Davies M. J., A review of neuraxial epidural morbidity : experience of more than 8,000 cases at a single teaching hospital. ANESTHESIOLOGY, 106, 997-1002, 2007. (Pubitemid 46684067)
4. Christie I. W., McCabe S., Major complications of epidural analgesia after surgery : results of a six-year survey, ANAESTHESIA, 62, 335-341, 2007. (Pubitemid 46487243)
5. Cook T. M., Counsell D., Wildsmith J. A., Major complications of central neuraxial block : report on the Third National Audit Project of the Royal College of Anaesthetists, BR. J. ANAESTH., 102, 179-190, 2009.
6. Moen V., Dahlgren N., Irestedt L., Severe neurological complications after central neuraxial blockades in Sweden 1990-1999, ANESTHESIOLOGY, 101, 950-959, 2004. (Pubitemid 39288046)
7. Schroeder D. R., Statistics : detecting a rare adverse drug reaction using spontaneous reports, REG. ANESTH. PAIN MED., 23, 183-189, 1998. (Pubitemid 28531571)
8. Rosencher N., Bonnet M. P., Sessler D. I., Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery : management strategies, ANAESTHESIA, 62, 1154-1160, 2007. (Pubitemid 47556416)
9. Poldermans D., Bax J. J., Boersma E., et al., Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery, EUR. HEART J., 30, 2769-2812, 2009.
10. Gogarten W., Vandermeulen E., Van Aken H., Kozek S., Llau J. V., Samama C. M., Regional anaesthesia and antithrombotic agents : recommendations of the European Society of Anaesthesiology, EUR. J. ANAESTHESIOL., 27, 999-1015, 2010.
11. Ruppen W., Derry S., McQuay H. J., Moore R. A., Incidence of epidural haematoma and neurological injury in cardiovascular patients with epidural analgesia/anaesthesia : systematic review and meta-analysis, BMC ANESTHESIOL., 6, 10, 2006.
12. Vandermeulen E. P., Van Aken H., Vermylen J., Anticoagulants and spinal-epidural anesthesia, ANESTH. ANALG., 79, 1165-1177, 1994. (Pubitemid 24363624)
13. Lee L. A., Posner K. L., Domino K. B., Caplan R. A., Cheney F. W., Injuries associated with regional anesthesia in the 1980s and 1990s : a closed claims analysis, ANESTHESIOLOGY, 101, 143-152, 2004. (Pubitemid 38833275)
14. Tryba M., Epidural regional anesthesia and low molecular heparin : Pro (German), ANÄSTHESIOL. INTENSIVMED. NOTFALLMED. SCHMERZTHER., 28, 179-181, 1993. (Pubitemid 23193156)
15. Horlocker T. T., Heit J. A., Low molecular weight heparin : biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management, ANESTH. ANALG., 85, 874-885, 1997. (Pubitemid 27418898)
16. Popping D. M., Zahn P. K., Van Aken H. K., Dasch B., Boche R., Pogatzki-Zahn E. M., Effectiveness and safety of postoperative pain management : a survey of 18 925 consecutive patients between 1998 and 2006 (2nd revision) : a database analysis of prospectively raised data, BR. J. ANAESTH., 101, 832-840, 2008.
17. Ruppen W., Derry S., McQuay H., Moore R. A., Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia/anesthesia, ANESTHESIOLOGY, 105, 394-399, 2006. (Pubitemid 44148185)
18. Vandermeulen E., Is anticoagulation and central neural blockade a safe combination, CURR. OPIN. ANAESTHESIOL., 12, 539-543, 1999. (Pubitemid 30026074)
19. Horlocker T. T., Wedel D. J., Neurologic complications of spinal and epidural anesthesia, REG. ANESTH. PAIN MED., 25, 83-98, 2000. (Pubitemid 30059183)
20. Wulf H., Epidural anaesthesia and spinal hematoma, CAN. J. ANAESTH., 43, 1260-1271, 1996.
21. Hebl J. R., Horlocker T. T., Kopp S. L., Schroeder D. R., Neuraxial blockade in patients with preexisting spinal stenosis, lumbar disk disease, or prior spine surgery : efficacy and neurologic complications, ANESTH. ANALG., 111, 1511-1519, 2010.
22. Horlocker T. T., Wedel D. J., Neuraxial block and low-molecular-weight heparin : balancing perioperative analgesia and thromboprophylaxis, REG. ANESTH. PAIN MED., 23, 164-177, 1998. (Pubitemid 28531569)
23. Lawton M. T., Porter R. W., Heiserman J. E., Jacobowitz R., Sonntag V. K., Dickman C. A., Surgical management of spinal epidural hematoma : relationship between surgical timing and neurological outcome, J. NEUROSURG., 83, 1-7, 1995.
24. Meikle J., Bird S., Nightingale J. J., White N., Detection and management of epidural haematomas related to anaesthesia in the UK : a national survey of current practice, BR. J. ANAESTH., 101, 400-404, 2008.
25. Strebel N., Prins M., Agnelli G., Buller H. R., Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery ?, ARCH. INTERN. MED., 162, 1451-1456, 2002. (Pubitemid 34747477)
26. Hull R. D., Pineo G. F., Stein P. D., et al., Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty : a systematic review, ARCH. INTERN. MED., 161, 1952-1960, 2001.
27. Raskob G. E., Hirsh J., Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. CHEST, 124, 379S-385S, 2003. (Pubitemid 38005465)
28. Geerts W. H., Bergqvist D., Pineo G. F., et al., Prevention of venous thromboembolism : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), CHEST, 133, 381S-453S, 2008. (Pubitemid 351894916)
29. Kehlet H., Holte K., Effect of postoperative analgesia on surgical outcome, BR. J. ANAESTH., 87, 62-72, 2001. (Pubitemid 32631676)
30. Rodgers A., Walker N., Schug S., et al., Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia : results from overview of randomised trials, BMJ, 321, 1493, 2000.
31. Modig J., Borg T., Karlstrom G., Maripuu E., Sahlstedt B., Thromboembolism after total hip replacement : role of epidural and general anesthesia, ANESTH. ANALG., 62, 174-180, 1983. (Pubitemid 13140287)
32. Prins M. H., Hirsh J., A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery : a critical review, THROMB. HAEMOST., 64, 497-500, 1990.
33. Warkentin T. E., Levine M. N., Hirsh J., et al., Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin, N. ENGL. J. MED., 332, 1330-1335, 1995.
34. Harenberg J., Jorg I., Fenyvesi T., Heparin-induced thrombocytopenia : pathophysiology and new treatment options, PATHOPHYSIOL. HAEMOST. THROMB., 32, 289-294, 2002. (Pubitemid 37490555)
35. Rao T. L., El-Etr A. A., Anticoagulation following placement of epidural and subarachnoid catheters : An evaluation of neurologic sequelae. ANESTHESIOLOGY, 55, 618-620, 1981. (Pubitemid 12253907)
36. Stafford-Smith M., Impaired haemostasis and regional anaesthesia, CAN. J. ANAESTH., 43, R129-141, 1996. (Pubitemid 26186769)
37. Chaney M. A., Cardiac surgery and intrathecal/epidural techniques : at the crossroads?, CAN. J. ANAESTH., 52, 783-788, 2005. (Pubitemid 41723650)
38. Svircevic V., Nierich A. P., Moons K. G., et al., Thoracic epidural anesthesia for cardiac surgery : a randomized trial, ANESTHESIOLOGY, 114, 262-270, 2011.
39. Svircevic V., van Dijk D., Nierich A. P., et al., Meta-analysis of thoracic epidural anesthesia versus general anesthesia for cardiac surgery, ANESTHESIOLOGY, 114, 271-282, 2011.
40. Ho A. M., Chung D. C., Joynt G. M., Neuraxial blockade and hematoma in cardiac surgery : estimating the risk of a rare adverse event that has not (yet) occurred, CHEST, 117, 551-555, 2000. (Pubitemid 30111610)
41. Boneu B., Necciari J., Cariou R., et al., Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man, THROMB. HAEMOST., 74, 1468-1473, 1995. (Pubitemid 26018663)
42. GlaxoSmithKline. Fondaparinux : EPAR- Product information. 2009 [updated 11/04/2011; last accessed 02/05/2011]; Available from: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Product- Information/human/000403/ WC500027746.pdf.
43. Kwong L. M., Muntz J. E., Thromboprophylaxis dosing : the relationship between timing of first administration, efficacy, and safety, AM. J. ORTHOP., 31, 16-20, 2002.
44. Warkentin T. E., Greinacher A., Koster A., Lincoff A. M., Treatment and prevention of heparin-induced thrombocytopenia : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), CHEST, 133, 340S-380S, 2008. (Pubitemid 351892970)
45. Singelyn F. J., Verheyen C. C., Piovella F., Van Aken H. K., Rosencher N., The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter : the EXPERT Study, ANESTH. ANALG., 105, 1540-1547, table of contents, 2007.
46. Eriksson B. I., Borris L. C., Friedman R. J., et al., Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N. ENGL. J. MED., 358, 2765-2775, 2008. (Pubitemid 351930851)
47. Cleland J. G., Coletta A. P., Buga L., et al., Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT, EUR. J HEART FAIL., 13, 460-465, 2011.
48. Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee. FDA Advisory Committee Briefing Document (March 29, 2009). 2009 [last accessed 18/04/2011]; Available from: http://www.fda.gov/ohrms/dockets/ac/09/ briefing/2009-4418b1-01-FDA.pdf.
49. Bayer. Xarelto : EPAR - Product Information. 2009 [updated 04/03/2011; last accessed 23/04/2011]; Available from : http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR---Product- Information/human/000944/WC500057108.pdf.
50. Weitz J. I., Hirsh J., Samama M. M., New antithrombotic drugs : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), CHEST, 133, 234S-256S, 2008. (Pubitemid 351892968)
51. Raghavan N., Frost C. E., Yu Z., et al., Apixaban metabolism and pharmacokinetics after oral administration to humans, DRUG METAB. DISPOS., 37, 74-81, 2009.
52. Lassen M. R., Raskob G. E., Gallus A., Pineo G., Chen D., Portman R. J., Apixaban or enoxaparin for thromboprophylaxis after knee replacement, N. ENGL. J. MED., 361, 594-604, 2009.
53. Lassen M. R., Gallus A., Raskob G. E., Pineo G., Chen D., Ramirez L. M., Apixaban versus enoxaparin for thromboprophylaxis after hip replacement, N. ENGL. J. MED., 363, 2487-2498, 2010.
54. Lassen M. R., Raskob G. E., Gallus A., Pineo G., Chen D., Hornick P., Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2) : a randomised double-blind trial. LANCET, 375, 807-815, 2010.
55. Douketis J. D., Pharmacologic properties of the new oral anticoagulants : a clinician-oriented review with a focus on perioperative management, CURR. PHARM. DES., 16, 3436-3441, 2010.
56. Greinacher A., Lepirudin for the treatment of heparin-induced thrombocytopenia. In : Warkentin TE., Greinacher A., eds. Heparin-induced Thrombocytopenia. New York : Marcel Dekker; 2004. p. 397-436.
57. Eichler P., Friesen H. J., Lubenow N., Jaeger B., Greinacher A., Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin : incidence, effects on aPTT, and clinical relevance. BLOOD, 96, 2373-2378, 2000.
58. Warkentin T. E., Crowther M. A., Reversing anticoagulants both old and new, CAN. J. ANAESTH., 49, S11-25, 2002.
59. Poidevin P., Salome V., Riegel B., Verdin M. F., Bernard A., Krivosic-Horber R., [Recombinant hirudin in neurosurgery], ANN. FR. ANESTH. REANIM., 20, 570-572, 2001.
60. Eriksson B. I., Dahl O. E., Rosencher N., et al., Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement : the RE-MODEL randomized trial, J. THROMB. HAEMOST., 5, 2178-2185, 2007. (Pubitemid 47617868)
61. van Ryn J., Stangier J., Haertter S., et al., Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity, THROMB. HAEMOST., 103, 1116-1127, 2010.
62. Boehringer-Ingelheim. Dabigatran : EPAR - Product information. 2009 [updated 15/12/2009; last accessed 01/05/2011]; Available from: /http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product- Information/human/000829/WC500041059.pdf.
63. Vandermeulen E., Verhamme P., Periprocedural bridging of anticoagulation, ACTA ANAESTHESIOL. BELG., 61, 133-138, 2010.
64. Leese P. T., Hubbard R. C., Karim A., Isakson P.C., Yu S. S., Geis G. S., Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults : a randomized, controlled trial, J. CLIN. PHARMACOL., 40, 124-132, 2000.
65. Sacco R. L., Diener H. C., Yusuf S., et al., Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke, N. ENGL. J. MED., 359, 1238-1251, 2008.
66. Tantry U. S., Bliden K. P., Gurbel P. A., Prasugrel, EXPERT OPIN. INVESTIG. DRUGS, 15, 1627-1633, 2006. (Pubitemid 44848984)
67. Farid N. A., Smith R. L., Gillespie T. A., et al., The disposition of prasugrel, a novel thienopyridine, in humans, DRUG METAB. DISPOS., 35, 1096-1104, 2007. (Pubitemid 46956429)
68. Wiviott S.D., Braunwald E., McCabe C. H., et al., Prasugrel versus clopidogrel in patients with acute coronary syndromes, N. ENGL. J. MED., 357, 2001-2015, 2007. (Pubitemid 350106708)
69. Montalescot G., Wiviott S. D., Braunwald E., et al., Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38) : double-blind, randomised controlled trial, LANCET, 373, 723-731, 2009.
70. Lilly S. A. Prausugrel : EPAR - Product information. 2009 [updated 2/12/2009; last accessed 02/05/2011]; Available from : http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Product-Inforrnation/human/000984/ WC500021971.pdf.
71. Giorgi M. A., Cohen Arazi H., Gonzalez C.D., Di Girolamo G., Beyond efficacy : pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor, EXPERT OPIN. PHARMACOTHER., 2011.
72. Nawarskas J. J., Clark S. M., Ticagrelor: a novel reversible oral antiplatelet agent, CARDIOL. REV., 19, 95-100, 2011.
73. Abergel E., Nikolsky E., Ticagrelor : an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome, VASC. HEALTH RISK. MANAG., 6, 963-977, 2010.
74. Gaglia M. A., Jr., Waksman R., Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor, CIRCULATION, 123, 451-456, 2011.
75. Gurbel P. A., Bliden K. P., Butler K., et al., Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease : the ONSET/OFFSET study, CIRCULATION, 120, 2577-2585, 2009.
76. Kowalczyk M., Banach M., Mikhailidis D. P., Hannam S., Rysz J., Ticagrelor - a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors ?, MED. Sci. MONIT., 15, MS24-30, 2009.
77. Wallentin L., Becker R. C., Budaj A., et al., Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N. ENGL. J. MED., 361, 1045-1057, 2009.
78. Serebruany V. L., The TRITON versus PLATO trials : differences beyond platelet inhibition, THROMB. HAEMOST., 103, 259-261, 2010.
79. AstraZeneca. Brilique : EPAR - product information. 2011 [updated 07/01/2011; last accessed 19/06/2011]; Available from : http://www.ema.europa. eu/docs/en-GB/document-library/EPAR---Product- Information/human/001241/ WC500100494.pdf.
80. Steinhubl S. R., Assessing platelet junction during treatment with glycoprotein IIb/IIIa antagonists, CORON. ARTERY DIS., 14, 381-386, 2003. (Pubitemid 36994043)
81. Wheeler G. L., Braden G. A., Steinhubl S. R., et al., The Ultegra rapid platelet-function assay : comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy, AM. HEART. J., 143, 602-611, 2002. (Pubitemid 34454692)
82. Dasgupta H., Blankenship J. C., Wood G. C., Frey C. M., Demko S. L., Menapace F. J., Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors : a pooled analysis, AM. HEART. J., 140, 206-211, 2000. (Pubitemid 30641579)
83. Huang F., Hong E., Platelet glycoprotein IIb/IIIa inhibition and its clinical use, CURR MED. CHEM. CARDIOVASC. HEMATOL. AGENTS, 2, 187-196, 2004. (Pubitemid 38854980)
84. Rosove M. H., Platelet glycoprotein IIb/IIIa inhibitors, BEST. PRACT. RES. CLIN. HAEMATOL., 17, 65-76, 2004.
85. Bakish D., Cavazzoni P., Chudzik J., Ravindran A., Hrdina P. D., Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder, BIOL. PSYCHIATRY, 41, 184-190, 1997. (Pubitemid 27062658)
86. Butler J., Leonard B. E., The platelet serotonergic system in depression and following sertraline treatment, INT. CLIN. PSYCHOPHARMACOL., 3, 343-347, 1988.
87. Helmeste D. M., Tang S. W., Reist C., Vu R., Serotonin uptake inhibitors modulate intracellular Ca2+ mobilization in platelets, EUR. J. PHARMACOL., 288, 373-377, 1995.
88. Markovitz J. H., Shuster J. L., Chitwood W. S., May R. S., Tolbert L. C., Platelet activation in depression and effects of sertraline treatment : An open-label study, AM. J. PSYCH., 157, 1006-1008, 2000. (Pubitemid 30412355)
89. Bassotti G., Nzepa F. S., de Roberto G., Fischer M. J., Morelli A., Symptomatic reversible duodenal compression due to iatrogenic retroperitoneal hematoma, DIGEST. LIVER DIS., 36, 78-81, 2004. (Pubitemid 41122229)
90. Nelva A., Guy C., Tardy-Poncet B., et al., [Hemorrhagic syndromes related to selective serotonin reuptake inhibitor (SSRI) antidepressants. Seven case reports and review of the literature], REV. MED. INT., 21, 152-160, 2000. (Pubitemid 30099967)
91. Norred C. L., Finlayson C. A., Hemorrhage after the preoperative use of complementary and alternative medicines, AANA J., 68, 217-220, 2000. (Pubitemid 30421767)
92. Sewnath M. E., van Hillegersberg R., Koopman M. M., Levi M. M., Gouma D. J., [Increased perioperative blood loss during treatment with paroxetine], NED. TIJDSCHR. GENEESKD., 146, 1800-1802, 2002.
93. .Vandel P., Vandel S., Kantelip J. P., SSRI-induced bleeding : two case reports, THERAPIE, 56, 445-447, 2001.
94. van Walraven C., Mamdani M. M., Wells P. S., Williams J. I., Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients : retrospective cohort study, BMJ, 323, 655-658, 2001. (Pubitemid 32897004)
95. Movig K. L., Janssen M. W., de Waal Malefijt J., Kabel P. J., Leufkens H. G., Egberts A. C., Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients, ARCH. INTERN. MED., 163, 2354-2358, 2003. (Pubitemid 37310197)
96. Gartner R., Cronin-Fenton D., Hundborg H. H., et al., Use of selective serotonin reuptake inhibitors and risk of reoperation due to post-surgical bleeding in breast cancer patients : a Danish population-based cohort study, BMC SURGERY, 10, 3, 2010.
97. Andreasen J. J., Riis A., Hjortdal V. E., Jorgensen J., Sorensen H. T., Johnsen S. P., Effect of selective serotonin reuptake inhibitors on requirement for allogeneic red blood cell transfusion following coronary artery bypass surgery, AM. J. CARDIOVASC. DRUGS, 6, 243-250, 2006. (Pubitemid 44285133)
98. Kim D. H., Daskalakis C., Whellan D. J., et al., Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting, AM. J. CARDIOL., 103, 1391-1395, 2009.
99. Xiong G. L., Jiang W., Clare R. M., et al., Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting, CLIN. CARDIOL., 33, E94-98, 2010.
100. Halperin D., Reber G., Influence of antidepressants on hemostasis, DIAL. CLIN. NEUROSCI., 9, 47-59, 2007.
101. Dalton S. O., Johansen C., Mellemkjaer L., Norgard B., Sorensen H. T., Olsen J. H., Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding : a population-based cohort study, ARCH. INTERN. MED., 163, 59-64, 2003. (Pubitemid 36091601)
102. de Maistre E., Allart C., Lecompte T., Bollaert P. E., Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors, AM. J. MED., 113, 530-532, 2002. (Pubitemid 35335812)
103. Loke Y. K., Trivedi A.N., Singh S., Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. ALIMENT. PHARMACOL. THERAP., 27, 31-40, 2008. (Pubitemid 350212624)
104. Schalekamp T., Klungel O. H., Souverein P. C., de Boer A., Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins, ARCH. INTERN. MED., 168, 180-185, 2008. (Pubitemid 351185885)
105. Wallerstedt S. M., Gleerup H., Sundstrom A., Stigendal L., Ny L., Risk of clinically relevant bleeding in warfarin-treated patients - influence of SSRI treatment, PHARMACOEPIDEMIOL. DRUG SAF., 18,4 12-416, 2009.
106. Rose K. D., Croissant P. D., Parliament C. F., Levin M. B., Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion : a case report, NEUROSURGERY, 26, 880-882, 1990. (Pubitemid 20152635)
107. Beckert B. W., Concannon M. J., Henry S. L., Smith D. S., Puckett C. L., The effect of herbal medicines on platelet function : an in vivo experiment and review of the literature, PLAST. RECONSTR. SURG., 120, 2044-2050, 2007. (Pubitemid 350306707)
108. Kohler S., Funk P., Kieser M., Influence of a 7-day treatment with Ginkgo biloba special extract EGb 761 on bleeding time and coagulation : a randomized, placebo-controlled, double-blind study in healthy volunteers, BLOOD COAGUL. FIBRINOLYSIS, 15, 303-309, 2004.
109. Horlocker T. T., Wedel D. J., Rowlingson J. C., et al., Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy : American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition), REG. ANESTH. PAIN MED., 35, 64-101, 2010.